Evidence map›Paper›PMID 35360223›Full record

ArticleFrontiers in physiology2022

High-Throughput Metabolomics Platform for the Rapid Data-Driven Development of Novel Additive Solutions for Blood Storage.

Travis Nemkov, Tatsuro Yoshida, Maria Nikulina, Angelo D'Alessandro

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Curcumin's Protective Effects Against HMolecules (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. HypomorphicHemaSphere · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Travis NemkovOmix Technologies Inc., Denver, CO, United States.
Tatsuro YoshidaHemanext Inc., Lexington, MA, United States.
Maria NikulinaHemanext Inc., Lexington, MA, United States.
Angelo D'AlessandroOmix Technologies Inc., Denver, CO, United States.
Hemanext (United States) · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · US

Funding

The Impact of Oxidative Stress on Erythocyte BiologyR01HL148151 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI D'ALESSANDRO, ANGELO, KARAFIN, MATTHEW S · 2019 to 2022
$8.9M
The role of ferroptosis in red cell aging in vivo and in vitroR01HL146442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Angelo D'Alessandro, Adam N. Goldfarb · 2019 to 2026
$5.4M
Regulatory Approval & Commercialization of an RBC Processing and Storage System to Improve Transfusion Therapy by Minimizing Oxidative Damage to RBC during StorageR44HL132172 · NHLBI · NEW HEALTH SCIENCES, INC. · PI DUNHAM, ANDREW, YOSHIDA, TATSURO · 2016 to 2018
$3.0M
The paradoxical response to iron in pulmonary hypertension of sickle cell diseaseR01HL161004 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BUEHLER, PAUL WERNER, D'ALESSANDRO, ANGELO · 2022 to 2025
$2.7M
Interactions between the ADORA2b/Sphk1axis and the AE1-Hb switch in red blood cell aging in vivo and in vitroR01HL149714 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI D'ALESSANDRO, ANGELO · 2020 to 2023
$2.6M
An additive solution optimized for anaerobic (hypoxic) RBC storage to minimize storage lesion development.R44HL149579 · NHLBI · NEW HEALTH SCIENCES, INC. · PI NEMKOV, TRAVIS, YOSHIDA, TATSURO · 2020 to 2021
$1.5M
MIRAGES: Metabolic Investigation of Red blood cells as a function of Aging, Genetics, Environment, and StorageR21HL150032 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI D'ALESSANDRO, ANGELO · 2020 to 2021
$414k
NHLBI NIH HHS R01 HL146442NHLBI NIH HHS R01 HL148151NHLBI NIH HHS R01 HL149714NHLBI NIH HHS R01 HL161004NHLBI NIH HHS R21 HL150032NHLBI NIH HHS R44 HL132172NHLBI NIH HHS R44 HL149579
6 · The paper itself

Abstract

Red blood cell transfusion is a life-saving intervention, and storage is a logistic necessity to make ~110 million units available for transfusion every year worldwide. However, storage in the blood bank is associated with a progressive metabolic decline, which correlates with the accumulation of morphological lesions, increased intra- and extra-vascular hemolysis upon transfusion, and altered oxygen binding/off-loading kinetics. Prior to storage, red blood cells are suspended in nutrient formulations known as additive solutions to prolong cellular viability. Despite a thorough expansion of knowledge regarding red blood cell biology over the past few decades, only a single new additive solution has been approved by the Food and Drug Administration this century, owing in part to the limited capacity for development of novel formulations. As a proof of principle, we leveraged a novel high-throughput metabolomics technology as a platform for rapid data-driven development and screening of novel additive solutions for blood storage under both normoxic and hypoxic conditions. To this end, we obtained leukocyte-filtered red blood cells (RBCs) and stored them under normoxic or hypoxic conditions in 96 well plates (containing polyvinylchloride plasticized with diethylhexylphthalate to concentrations comparable to full size storage units) in the presence of an additive solution supplemented with six different compounds. To inform this data-driven strategy, we relied on previously identified metabolic markers of the RBC storage lesion that associates with measures of hemolysis and post-transfusion recovery, which are the FDA gold standards to predict stored blood quality, as well as and metabolic predictors of oxygen binding/off-loading parameters. Direct quantitation of these predictors of RBC storage quality were used here-along with detailed pathway analysis of central energy and redox metabolism-as a decision-making tool to screen novel additive formulations in a multiplexed fashion. Candidate supplements are shown here that boost-specific pathways. These metabolic effects are only in part dependent on the SO

Indexed as

high-throughput screeningmetabolismmethioninered blood cellstoragetransfusion medicine

Identifiers

PMID35360223
PMCPMC8964052
OpenAlexW4220941514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.